Proteon's vonapanitase receives breakthrough therapy designation

Proteon Therapeutics Inc. (NASDAQ:PRTO) said FDA granted breakthrough therapy designation to vonapanitase

Read the full 129 word article

How to gain access

Continue reading with a
two-week free trial.